Beth Hahn

2.3k total citations
72 papers, 1.8k citations indexed

About

Beth Hahn is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Ecology. According to data from OpenAlex, Beth Hahn has authored 72 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Physiology, 30 papers in Pulmonary and Respiratory Medicine and 12 papers in Ecology. Recurrent topics in Beth Hahn's work include Asthma and respiratory diseases (32 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers) and Respiratory and Cough-Related Research (15 papers). Beth Hahn is often cited by papers focused on Asthma and respiratory diseases (32 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers) and Respiratory and Cough-Related Research (15 papers). Beth Hahn collaborates with scholars based in United States, Canada and United Kingdom. Beth Hahn's co-authors include Leonard Kirchdoerfer, Emeran A. Mayer, S Fullerton, Scott A. Strassels, Songkai Yan, Emily Silverman, Nicholas Wells, Peter J. Whorwell, Héctor Ortega and Jean‐Pierre Llanos and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and PEDIATRICS.

In The Last Decade

Beth Hahn

71 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beth Hahn United States 20 669 548 321 317 268 72 1.8k
Ihunnaya O. Frederick United States 26 576 0.9× 469 0.9× 286 0.9× 493 1.6× 236 0.9× 41 4.3k
A. Pathmeswaran Sri Lanka 25 102 0.2× 84 0.2× 84 0.3× 197 0.6× 101 0.4× 139 3.3k
Agneta Hörnell Sweden 25 275 0.4× 361 0.7× 36 0.1× 205 0.6× 229 0.9× 57 2.4k
Todd Jenkins United States 29 138 0.2× 992 1.8× 111 0.3× 2.1k 6.6× 209 0.8× 144 3.6k
John Hinton United Kingdom 22 520 0.8× 115 0.2× 83 0.3× 630 2.0× 354 1.3× 54 2.4k
Marie‐Jo Brion United Kingdom 21 79 0.1× 421 0.8× 120 0.4× 240 0.8× 78 0.3× 34 3.5k
M Gelfand United States 19 351 0.5× 74 0.1× 170 0.5× 480 1.5× 102 0.4× 92 1.4k
R. Hankard France 33 55 0.1× 581 1.1× 165 0.5× 330 1.0× 123 0.5× 122 2.7k
Margaret G. Parker United States 28 86 0.1× 99 0.2× 344 1.1× 112 0.4× 229 0.9× 97 2.3k
Sue Woodward United Kingdom 18 149 0.2× 52 0.1× 31 0.1× 222 0.7× 60 0.2× 117 1.1k

Countries citing papers authored by Beth Hahn

Since Specialization
Citations

This map shows the geographic impact of Beth Hahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Hahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Hahn more than expected).

Fields of papers citing papers by Beth Hahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Hahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Hahn. The network helps show where Beth Hahn may publish in the future.

Co-authorship network of co-authors of Beth Hahn

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Hahn. A scholar is included among the top collaborators of Beth Hahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Hahn. Beth Hahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Underwood, Emma C., Allan D. Hollander, & Beth Hahn. (2024). Assessing Trends in Tree Cover, Wildfire and Population Growth in Zimbabwe since 2000. Land. 13(2). 160–160. 1 indexed citations
2.
Salisbury, David, Jeffrey V. Lazarus, Nancy M. Waite, et al.. (2024). COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment. JMIR Public Health and Surveillance. 10. e57242–e57242. 2 indexed citations
3.
Casale, Thomas B., et al.. (2022). Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies. Therapeutic Advances in Respiratory Disease. 16. 2673686641–2673686641. 10 indexed citations
4.
Sethi, Sanjay, et al.. (2022). Impact of Mepolizumab on Exacerbations in the US Medicare Population. The Journal of Allergy and Clinical Immunology In Practice. 11(2). 546–554.e2. 2 indexed citations
5.
Moretz, Chad, Guillaume Germain, François Laliberté, et al.. (2021). Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease. Pulmonary Therapy. 7(1). 203–219. 4 indexed citations
6.
Silver, Jared, Michael Bogart, Néstor A. Molfino, et al.. (2021). Factors leading to discontinuation of biologic therapy in patients with severe asthma. Journal of Asthma. 59(9). 1839–1849. 14 indexed citations
7.
Kalhan, Ravi, Chad Moretz, Guillaume Germain, et al.. (2021). Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities. International Journal of COPD. Volume 16. 1149–1161. 5 indexed citations
8.
9.
Oppenheimer, John, Beth Hahn, L. Zografos, et al.. (2020). Real-world evidence. Annals of Allergy Asthma & Immunology. 126(4). 385–393.e2. 14 indexed citations
10.
Moretz, Chad, et al.. (2020). Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. SHILAP Revista de lepidopterología. 1 indexed citations
11.
12.
Moretz, Chad, et al.. (2019). Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. SHILAP Revista de lepidopterología.
13.
Llanos, Jean‐Pierre, Christopher F. Bell, Elizabeth Packnett, et al.. (2019). <p>Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study</p>. Journal of Asthma and Allergy. Volume 12. 43–58. 13 indexed citations
14.
15.
Han, MeiLan K., et al.. (2018). Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD. npj Primary Care Respiratory Medicine. 28(1). 32–32. 7 indexed citations
16.
Buikema, Ami, Lee Brekke, Amy Anderson, et al.. (2018). The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidisciplinary Respiratory Medicine. 13(1). 38–38. 8 indexed citations
17.
Hahn, Beth, et al.. (2018). Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. Respiratory Medicine. 139. 65–71. 14 indexed citations
18.
Weißenborn, Anke, Renate L. Bergmann, Beth Hahn, et al.. (2015). Stillhäufigkeit und Stilldauer in Deutschland – eine systematische Übersicht. Das Gesundheitswesen. 78(11). 695–707. 13 indexed citations
19.
Hahn, Beth, Leonard Kirchdoerfer, S Fullerton, & Emeran A. Mayer. (1997). Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 11(3). 547–552. 158 indexed citations
20.
Hahn, Beth. (1994). Health Care Utilization: The Effect of Extending Insurance to Adults on Medicaid or Uninsured. Medical Care. 32(3). 227–239. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ihunnaya O. Frederick Breakdown of academic impact, for papers by A. Pathmeswaran Breakdown of academic impact, for papers by Agneta Hörnell Breakdown of academic impact, for papers by Todd Jenkins Breakdown of academic impact, for papers by John Hinton Breakdown of academic impact, for papers by Marie‐Jo Brion Breakdown of academic impact, for papers by M Gelfand Breakdown of academic impact, for papers by R. Hankard Breakdown of academic impact, for papers by Margaret G. Parker Breakdown of academic impact, for papers by Sue Woodward
Rankless by CCL
2026